Patents by Inventor Reinier Boon

Reinier Boon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction
    Publication number: 20180023080
    Abstract: The present invention associates multiplelong non-coding RNA (lncRNA) with key functions of endothelial cells. The lncRNA of the present invention are therefore useful as novel drug targets for the manufacturing of medicines for the treatment of cardiovascular diseases or pathological angiogenesis in context of proliferative diseases such as cancer. Modulation of the function or expression of the lncRNA of invention can induce or repress angiogenesis and vessel growth or repair in endothelial cells. Provided are further methods for the modulation of endothelial cell functions in vitro, for example, in the context of tissue engineering.
    Type: Application
    Filed: February 3, 2016
    Publication date: January 25, 2018
    Inventors: Stefanie DIMMELER, Reinier BOON, Nicolas JAÉ, Katharina MICHALIK
  • Antagonists of miRNA-29 expression and their use in the prevention and treatment of aneurysm
    Patent number: 9062307
    Abstract: The present invention relates to antagonists of the expression and/or the function of the micro RNA miRNA-29 for use in the prevention and/or treatment of aortic aneurysms. Further disclosed is a method for the identification of miRNA-29 antagonists, a pharmaceutical composition comprising said miRNA-29 antagonists and a method for preventing and treating age-related aortic aneurysm formation in a subject in need of such a treatment.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: June 23, 2015
    Assignee: Johann Wolfgang Goethe-Universität Frankfurt am Main
    Inventors: Andreas Zeiher, Stefanie Dimmeler, Reinier Boon
  • Micro-RNA for the regulation of cardiac apoptosis and contractile function
    Patent number: 8871731
    Abstract: The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: October 28, 2014
    Assignee: Migagen Therapeutics, Inc.
    Inventors: Stefanie Dimmeler, Reinier A. Boon, Ariane Fischer, Andreas M. Zeiher
  • Antagonists of miRNA-29 Expression and Their Use in the Prevention and Treatment of Aneurysm
    Publication number: 20130116303
    Abstract: The present invention relates to antagonists of the expression and/or the function of the micro RNA miRNA-29 for use in the prevention and/or treatment of aortic aneurysms. Further disclosed is a method for the identification of miRNA-29 antagonists, a pharmaceutical composition comprising said miRNA-29 antagonists and a method for preventing and treating age-related aortic aneurysm formation in a subject in need of such a treatment.
    Type: Application
    Filed: April 1, 2011
    Publication date: May 9, 2013
    Applicant: Johann Wolfgang Goethe-Universitat Frankfurt am Main
    Inventors: Andreas Zeiher, Stefanie Dimmeler, Reinier Boon
  • MICRO-RNA FOR THE REGULATION OF CARDIAC APOPTOSIS AND CONTRACTILE FUNCTION
    Publication number: 20120238619
    Abstract: The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity.
    Type: Application
    Filed: March 16, 2012
    Publication date: September 20, 2012
    Applicant: Miragen Therapeutics
    Inventors: Stefanie DIMMELER, Reinier A. Boon, Ariane Fischer, Andreas M. Zeiher